Enterprise Value (EV)
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Enterprise Value (EV)
Regeneron Pharmaceuticals Inc., current enterprise value calculation
| Current share price (P) | |
| No. shares of common stock outstanding | |
| US$ in thousands | |
| Common equity (market value)1 | |
| Add: Preferred Stock, par value $.01 per share; issued and outstanding: none (per books) | |
| Total equity | |
| Add: Finance lease liabilities, current portion (per books) | |
| Add: Long-term debt (per books) | |
| Add: Finance lease liabilities, excluding current portion (per books) | |
| Total equity and debt | |
| Less: Cash and cash equivalents | |
| Less: Marketable securities | |
| Enterprise value (EV) | |
Based on: 10-K (reporting date: 2025-12-31).
1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Historical Enterprise Value (EV)
Regeneron Pharmaceuticals Inc., EV calculation
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
3 2025 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
The enterprise value exhibited a generally increasing trend from 2021 to 2023, followed by declines in the subsequent two years. A consistent relationship exists between common equity (market value), total equity, and enterprise value throughout the observed period.
- Enterprise Value Trend
- Enterprise value increased from US$64.56 billion in 2021 to US$94.63 billion in 2023, representing a compound annual growth rate of approximately 13.7%. However, a decrease was observed in 2024, with enterprise value falling to US$72.05 billion, and this downward trend continued into 2025, reaching US$76.04 billion. The decline from the 2023 peak to 2025 represents a decrease of approximately 19.7%.
- Equity and Debt Relationship
- Total equity and debt consistently exceeded total equity throughout the period, indicating the presence of debt financing. The difference between total equity and total equity and debt represents the total debt. This total debt component appears to have a relatively stable contribution to the overall enterprise value.
- Common Equity and Enterprise Value
- Common equity (market value) and enterprise value moved in a similar pattern over the five years. The enterprise value consistently remained below the common equity (market value), suggesting a net cash position or a relatively low debt level when compared to market capitalization. The correlation between these two metrics suggests that changes in investor perception of the company’s equity value directly influence the enterprise value.
The fluctuations in enterprise value from 2023 to 2025 warrant further investigation to determine the underlying causes, such as changes in market conditions, company performance, or debt levels. The consistent relationship between equity components and enterprise value suggests that valuation is heavily influenced by equity market dynamics.